Lunai Bioworks will be at the BIO International Convention in San Diego on June 22-25, and we’re looking to connect with potential partners in biotech and drug discovery. #BIO2026#Biotech#Partnerships
We at Lunai Bioworks support this week’s open letter on nucleic acid synthesis screening and record-keeping. It shows broad alignment around practical biosecurity safeguards, including the CEOs of @OpenAI, @AnthropicAI, and @MicrosoftAI. #Biosecurity#Biodefense#AIinBiology
We see our work as part of that broader effort, with Sentinel on prevention, Pathfinder and @biosymetrics on threat assessment, and Counteract on medical countermeasure development.
BioSymetrics (a @lunaibioworks company) and BrainStorm Therapeutics have launched a strategic collaboration, backed by the LouLou Foundation, to discover and validate new therapeutic targets for neurological diseases. #Neurology#PrecisionMedicine#DrugDiscovery
Lunai Bioworks has completed and expanded our previously announced $20M CNS-focused transaction through the NeuroBridge IP acquisition, adding complementary brain-delivery capabilities to our CNS platform. #CNS#DrugDelivery#Neuroscience
Together, these capabilities are intended to support multi-agent strategies, meaning combinations of therapeutic agents with different mechanisms of action, and more targeted development with Augusta.
BioSymetrics (a @lunaibioworks company) signed a non-binding Letter of Intent with Geneial to build trial-ready cohorts from patient-led data, starting in select rare neurodevelopmental disorders. #RareDisease#ClinicalTrials#PrecisionMedicine
BioSymetrics (a @lunaibioworks company) is at the AWS Life Sciences Symposium in NYC today (April 14) at the Javits Center. If you’re here too, let’s connect. #LifeSciences#DrugDiscovery#AWS
BioSymetrics (a @lunaibioworks company) is heading to the AWS Life Sciences Symposium in NYC on Tuesday, April 14 at the Javits Center. If you’re attending, let’s connect. #LifeSciences#DrugDiscovery#AWS